Floatz logo

17 assets in Hemophilia

Therapeutic assets addressing Hemophilia, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Antihemophilic Factor, Human Recombinant
Hemophilia
Chulalongkorn UniversityP4BB (71)
Stsp-0601 For
Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.P3BB (70)
Immunoglobulin G1, Anti-(Human Tissue Factor Pathway Inhibitor) (Human Monoclonal Pf-06741086 .Gamma.1-Chain), Disulfide With Human Monoclonal Pf-06741086 .Lambda.-Chain, Dimer
Hemophilia
Institute of Hematology & Blood Diseases Hospital, ChinaP2BB (69)
Eptacog Alfa (Activated)
Hemophilia
Laboratoire français de Fractionnement et de BiotechnologiesP3BB (66)
Efanesoctocog Alfa
Hemophilia
Swedish Orphan BiovitrumP4BB (65)
Fitusiran
Hemophilia
SanofiP3BB (64)
kn057
Hemophilia
Suzhou Alphamab Co., Ltd.P3B (62)
Pcc
Hemophilia
Institute of Hematology & Blood Diseases Hospital, ChinaP4B (62)
Concizumab
Hemophilia
Novo Nordisk A/SP3B (60)
Antithrombin Iii
Hemophilia
SanofiP3B (57)
Dpc-A69448
Hemophilia
Hangzhou Gensciences Biopharmaceutical Co., Ltd.P1/2CCC (48)
mg1113
Hemophilia
GC Biopharma CorpP1CCC (48)
Valproic Acid
Hemophilia
Xue-chun LuP1/2CC (45)
Tranexamic Acid
Hemophilia
University of MinnesotaEarly P1C (38)
Autologous Conditioned Plasma
Hemophilia
University of UtahN/AD (30)
Xylitol
Hemophilia
Al-Azhar UniversityN/AD (30)